These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 25896699)

  • 1. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
    Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
    Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.
    Rudramurthy SM; Seyedmousavi S; Dhaliwal M; Chakrabarti A; Meis JF; Mouton JW
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
    Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
    Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
    Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
    Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
    Xu G; Zhu L; Ge T; Liao S; Li N; Qi F
    Int J Antimicrob Agents; 2016 Jun; 47(6):439-45. PubMed ID: 27179818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands.
    van Ingen J; van der Lee HA; Rijs TA; Zoll J; Leenstra T; Melchers WJ; Verweij PE
    J Antimicrob Chemother; 2015 Jan; 70(1):178-81. PubMed ID: 25301884
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Siopi M; Mouton JW; Pournaras S; Meletiadis J
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962332
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
    Wiederhold NP; Tam VH; Chi J; Prince RA; Kontoyiannis DP; Lewis RE
    Antimicrob Agents Chemother; 2006 Feb; 50(2):469-73. PubMed ID: 16436698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
    Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
    J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
    Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
    Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
    Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
    J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.
    Bellmann R
    Curr Pharm Des; 2013; 19(20):3629-47. PubMed ID: 23278532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B.
    Cornely OA; Maertens J; Bresnik M; Ullmann AJ; Ebrahimi R; Herbrecht R
    J Antimicrob Chemother; 2010 Jan; 65(1):114-7. PubMed ID: 19887460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Azole resistance in Aspergillus fumigatus in the Netherlands--increase due to environmental fungicides?].
    Verweij PE; van de Sande-Bruisma N; Kema GH; Melchers WJ
    Ned Tijdschr Geneeskd; 2012; 156(25):A4458. PubMed ID: 22748367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.
    Özmerdiven GE; Ak S; Ener B; Ağca H; Cilo BD; Tunca B; Akalın H
    J Infect Chemother; 2015 Aug; 21(8):581-6. PubMed ID: 26048062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of Azole Resistance in Aspergillus.
    Wiederhold NP; Patterson TF
    Semin Respir Crit Care Med; 2015 Oct; 36(5):673-80. PubMed ID: 26398534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.